Trial Outcomes & Findings for Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks (NCT NCT00329732)

NCT ID: NCT00329732

Last Updated: 2015-05-06

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

2 participants

Primary outcome timeframe

30 minutes

Results posted on

2015-05-06

Participant Flow

Participant milestones

Participant milestones
Measure
Lidocaine/Bupivicaine
Saline (Placebo)
Overall Study
STARTED
2
0
Overall Study
COMPLETED
2
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lidocaine/Bupivicaine
n=2 Participants
Saline (Placebo)
Total
n=2 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 participants
n=5 Participants
0 participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
2 participants
n=5 Participants
2 participants
n=5 Participants
Age, Categorical
>=65 years
0 participants
n=5 Participants
0 participants
n=5 Participants
Gender
Female
2 participants
n=5 Participants
2 participants
n=5 Participants
Gender
Male
0 participants
n=5 Participants
0 participants
n=5 Participants
Region of Enrollment
United States
2 participants
n=5 Participants
2 participants
n=5 Participants

PRIMARY outcome

Timeframe: 30 minutes

Population: No analysis was done. Study was terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 minutes

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 minutes

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 minutes

Outcome measures

Outcome data not reported

Adverse Events

Lidocaine/Bupivicaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Saline (Placebo)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Kathleen Bradley

Thomas Jefferson University

Phone: 215-955-2025

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place